NCT03574597
SUSTAIN — semaglutide long-term outcomes
Phase Phase 3
Status Completed
Indication Type 2 Diabetes
Enrollment 1,200
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT03574597
- Phase
- Phase 3
- Status
- Completed
- Indication
- Type 2 Diabetes
- Primary completion
- 8/1/2018
- Enrollment (planned/actual)
- 1,200
- Sponsor
- Novo Nordisk
- Peptide
- Semaglutide
Peptide under study
Semaglutide
GLP-1 receptor agonist · Approved